CCAP · Crescent Capital BDC, Inc.

The shares were sold in multiple transactions at prices ranging from $10.51 to $10.70 per share. The price reported reflects the volume weighted average price for the transactions. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares of common stock held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the Reporting Person.

The shares were sold in multiple transactions at prices ranging from $10.53 to $10.655 per share. The price reported reflects the volume weighted average price for the transactions. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares of common stock held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the Reporting Person.

The shares were sold in multiple transactions at prices ranging from $10.60 to $10.67 per share. The price reported reflects the volume weighted average price for the transactions. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares of common stock held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the Reporting Person.

The shares were sold in multiple transactions at prices ranging from $10.60 to $10.625 per share. The price reported reflects the volume weighted average price for the transactions. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares of common stock held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the Reporting Person.

The shares were sold in multiple transactions at prices ranging from $10.74 to $10.80 per share. The price reported reflects the volume weighted average price for the transactions. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares of common stock held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the Reporting Person.

The shares were sold in multiple transactions at prices ranging from $10.72 to $10.77 per share. The price reported reflects the volume weighted average price for the transactions. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares of common stock held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the Reporting Person.

Includes 1,137 shares acquired through dividend reinvestment in 2026 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.90 to $10.92, inclusive. Upon request by the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, the reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Includes 695 shares acquired through dividend reinvestment in 2026 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 945 shares acquired through dividend reinvestment in 2026 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.11 to $11.35, inclusive. Upon request by the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, the reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

1. Includes 2,088 shares acquired through dividend reinvestment in 2026 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 953 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 639 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Exchange Act of 1934.

Includes 2,556 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Exchange Act of 1934.

Includes 32 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 227 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 1,917 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Exchange Act of 1934.

Includes 12,779 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Exchange Act of 1934.

Includes 575 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 766 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.34 to $13.3499, inclusive. Upon request by the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, the reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Includes 2,627 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 64 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 1,181 shares acquired through dividend reinvestment in 2025 and not previously reported pursuant to Rule 16a-11 under the Securites Act of 1934.

Includes 2,187 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 632 shares acquired through dividend reinvestment in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 547 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 1,1041 shares acquired through dividend reinvestment in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 1,641 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 73 shares acquired through dividend reinvestment in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 2,747 shares acquired through dividend reinvestment in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 187 shares acquired through dividend reinvestment in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 10,937 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2024 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 1,495 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 9,968 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 86 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 71 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 1,994 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

Includes 498 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.

The reporting person received 3,022 shares as part of a pro rata distribution from Crescent CCAP 10b5-1 Associates LLC (the "Distribution"). No consideration was paid in connection with the Distribution, which was exempt from Section 16 pursuant to Rule 16a-9.

Includes 291 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc., in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Exchange Act of 1934.

The reporting person received 6,044 shares as part of a pro rata distribution from Crescent CCAP 10b5-1 Associates LLC (the "Distribution"). No consideration was paid in connection with the Distribution, which was exempt from Section 16 pursuant to Rule 16a-9.

The reporting person received 1,511 shares as part of a pro rata distribution from Crescent CCAP 10b5-1 Associates LLC (the "Distribution"). No consideration was paid in connection with the Distribution, which was exempt from Section 16 pursuant to Rule 16a-9.

Includes 2,503 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc., in 2023 and not previously reported pursuant to Rule 16a-11 under the Securities Exchange Act of 1934.

Includes 26 shares received by the reporting person in connection with the completion of the issuer's acquisition of First Eagle Alternative Capital BDC, Inc. ("FCRD") on March 9, 2023 pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2022 (the "FCRD Acquisition"). In accordance with the terms of the Merger Agreement, holders of shares of FCRD's common stock had their shares of FCRD common stock converted to the right to receive, in the aggregate, approximately (i) $8.6 million in cash payable by the issuer, (ii) 6,174,187 validly issued, fully paid and non-assessable shares of our common stock, and (ii) $35.0 million in cash payable by the issuer's investment adviser. The reporting person held 120 shares of FCRD common stock prior to the Merger Agreement and the FCRD Acquisition.

Includes 1,274 shares acquired under the Dividend Reinvestment Plan of Crescent Capital BDC, Inc. in 2022 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934.]